Delavirdine

Delavirdine (Rescriptor) is approved for the treatment of HIV-1 infection in adults and adolescents over age 16 as part of a combination therapy. Rash accompanied by pruritus is the most frequent adverse effect of this agent; however, it usually resolves within several weeks of treatment. Severe skin reactions are rare. Headache, nausea, vomiting, diarrhea, fatigue, and elevated hepatic enzymes also may be associated with delavirdine administration.

Drugs that decrease stomach acidity (e.g., antacids, H2 receptor blockers, and proton pump inhibitors) de crease the absorption of delavirdine. In vivo and in vitro studies have shown that delavirdine is metabolized by and inhibits CYP3A4. In vitro studies have shown that it also is metabolized by CYP2D6 and inhibits CYP2C9, CYP2D6, and CYP2C19. Delavirdine should not be used in combination with alprazolam, cisapride, ergot alkaloids, midazolam, or triazolam because of the potential for serious adverse reactions. Delavirdine increases serum concentrations of certain protease inhibitors and may reverse the resistance of zidovudine-resistant HIV.

101 Power Tips For Preventing and Treating Headaches

101 Power Tips For Preventing and Treating Headaches

Are you fed up with your frequent headache pain? 101 Simple Ways to Attack Your Headache BEFORE the Pain Starts Guaranteed No Pain, No Fear, Full Control Normal Life Again Headaches can stop you from doing all the things you love. Seeing friends, playing with the kids... even trying to watch your favorite television shows.

Get My Free Ebook


Post a comment